The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 03, 2024
Filed:
Dec. 16, 2021
H. Lundbeck A/s, Valby, DK;
Maria-Cristina Loomis, Bothell, WA (US);
Leon F. Garcia-Martinez, Woodinville, WA (US);
Benjamin H. Dutzar, Seattle, WA (US);
Daniel S. Allison, Lake Forest Park, WA (US);
Katherine Lee Hendrix, Renton, WA (US);
Ethan W. Ojala, Snohomish, WA (US);
Pei Fan, Bothell, WA (US);
Jeffrey T. L. Smith, Bellevue, WA (US);
John A. Latham, Seattle, WA (US);
Charlie Karasek, Seattle, WA (US);
Jenny Mulligan, Lake Forest Park, WA (US);
Michelle Scalley-Kim, Seattle, WA (US);
Erica Stewart, Seattle, WA (US);
Vanessa Lisbeth Rubin, Seattle, WA (US);
Jens J. Billgren, Bothell, WA (US);
H. LUNDBECK A/S, Valby, DK;
Abstract
The present invention is directed to antagonistic antibodies and antigen binding fragments thereof having binding specificity for PACAP. These antibodies inhibit, block or neutralize at least one biological effect associated with PACAP, e.g., vasodilation. In exemplary embodiments these antibodies and antigen binding fragments thereof may comprise specific V, V, and CDR polypeptides described herein. In some embodiments these antibodies and antigen binding fragments thereof bind to and/or compete for binding to specific epitope(s) on human PACAP. The invention is further directed to using these antagonistic anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, mast cell degranulation, and/or neuronal activation, are therapeutically beneficial, e.g., headache and migraine indications.